CoChat
Sign Up
Cited by 36Advanced Glycation End Products researchDialysis and Renal Disease ManagementChronic Kidney Disease and Diabetes

Tissue Advanced Glycation End Product Deposition after Kidney Transplantation

Crowley, Lisa E., Johnson, Catherine P., McIntyre, Natasha, Fluck, Richard J., McIntyre, Christopher W., Taal, Maarten W., Leung, Janson C.H.·2013·Nephron Clinical Practice
DOI 10.1159/000355692
Open this paper in CoChat — free account

Abstract

Background: Tissue advanced glycation end products (AGEs) accumulate in chronic kidney disease (CKD) and are a measure of cumulative metabolic stress. Measurement of tissue AGEs by skin autofluorescence (SAF) correlates well with cardiovascular outcomes in dialysis patients. SAF levels in transplant recipients relative to CKD and dialysis patients have not been previously studied, and the impact of transplantation on SAF levels in dialysis patients is unknown. Methods: SAF was measured using an AGE reader in 66 patients who had received a kidney transplant. Values were compared to those obtained in 1,707 patients with CKD stage 3 and in 115 patients on dialysis. Results: Mean SAF in transplant recipients [2.81 ± 0.64 arbitrary units (AU)] was significantly lower than in patients on haemodialysis (3.73 ± 0.88 AU) and peritoneal dialysis (3.57 ± 0.75 AU; p < 0.001), but was no different from CKD stage 3 (2.79 ± 0.66 AU; p = 0.42). In the transplant group, SAF correlated most strongly with age (r = 0.316). There was no correlation between SAF and estimated glomerular filtration rate or renal replacement therapy vintage. A small cohort of patients with SAF recorded on dialysis and following transplantation showed a drop in SAF over a mean time of 16 months after transplantation. Discussion: Tissue AGE values in kidney transplant recipients are significantly lower than in patients receiving dialysis and similar to those in patients with CKD stage 3. Our data suggest that transplantation may be associated with a reduction in tissue AGEs, and this might be an important component of the observed reduction in cardiovascular risk in transplant recipients compared to patients on dialysis.

Integrity signals

Registry

Crossref · 10.1159/000355692

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Acute/chronic kidney disease and end-stage renal failure can reduce AGE clearance, leading to accelerated progression and/or exacerbation of kidney malfunction and nephropathy.

    “On the other hand, acute/chronic kidney disease and end-stage renal failure can reduce AGE clearance. Consequently, glomerular and tubular cells are exposed to potentially harmful AGEs for extended periods of time owing to the lower rates of glomerular filtration. These changes lead to accelerated progression and/or exacerbation of kidney malfunction and nephropathy along with greater amounts of”

    From Advanced glycation end products (AGEs) and other adducts in aging-related diseases and alcohol-mediated tissue injury (2021) · cites this paper as [68]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Crowley, L. E., Johnson, C. P., McIntyre, N., Fluck, R. J., McIntyre, C. W., Taal, M. W., & Leung, J. C. H.
Affiliations
  • Royal Derby Hospital (GB)
  • University of Nottingham (GB)
ORCID
Venue
Nephron Clinical Practice
Publisher
S. Karger AG
Published
2013-10-15
Volume
124
Issue
1-2
Pages
54-59
ISSN
1660-2110 (ISSN-L)
DOI
10.1159/000355692
OpenAlex
W2081246062
Cited by
36
References
25
Citations by year
2024: 6 · 2023: 1 · 2022: 3 · 2021: 4 · 2020: 2 · 2019: 3 · 2018: 3 · 2017: 4 · 2016: 1 · 2015: 4 · 2014: 5
FWCI
2.20
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Nephron Clinical Practice (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Advanced Glycation End Products research
  • Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
Keywords
advanced glycation end products, skin autofluorescence, kidney transplantation, dialysis, chronic kidney disease, metabolic stress, cardiovascular risk, hemodialysis, peritoneal dialysis
MeSH terms
Aged, Female, Renal Dialysis, Humans, Male, Middle Aged, Sensitivity and Specificity, Skin, Reproducibility of Results, Kidney Transplantation, Glycation End Products, Advanced, Advanced Cardiac Life Support, Renal Insufficiency, Chronic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review